Listed

Addex Therapeutics Ltd.: Form 20-F for the period ended Dec 31, 2023

Filed with the SEC on Apr 18, 2024 and accepted by EDGAR at Apr 18, 2024, 06:15 ET.

Share

Share this page

Story card, 1080 × 1920

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.

Line itemPeriodValueXBRL concept
Revenue12 months2023-01-01 to 2023-12-31CHF 1.6mifrs-full:RevenueFromContractsWithCustomers
Operating income12 months2023-01-01 to 2023-12-31−CHF 10.3mifrs-full:ProfitLossFromOperatingActivities
Income tax12 months2023-01-01 to 2023-12-31CHF 0ifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2023-01-01 to 2023-12-31−CHF 10.6mifrs-full:ProfitLoss
Diluted EPS12 months2023-01-01 to 2023-12-31−CHF 0.14ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2023-01-01 to 2023-12-31−CHF 0.14ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2023-01-01 to 2023-12-31−CHF 8.0mifrs-full:CashFlowsFromUsedInOperatingActivities
Capital expenditure12 months2023-01-01 to 2023-12-31CHF 6.8kifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
Cash and equivalentsAt period end2023-12-31CHF 3.9mifrs-full:CashAndCashEquivalents
Current assetsAt period end2023-12-31CHF 4.2mifrs-full:CurrentAssets
Total assetsAt period end2023-12-31CHF 4.6mifrs-full:Assets
Current liabilitiesAt period end2023-12-31CHF 2.9mifrs-full:CurrentLiabilities
Shareholders' equityAt period end2023-12-31CHF 1.1mifrs-full:Equity
Shares outstandingAt period end2023-12-31125,195,393 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001104659-24-048532. Last ingested by Listed: Oct 29, 2026, 06:06 ET. Listed shows no prices and gives no investment advice.